D. E. Shaw & Co., Inc. Clovis Oncology, Inc. Call Options Transaction History

D. E. Shaw & Co., Inc.

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2019 Feb 14, 2020	BUY	$3.0 - $16.43 $90,000 - $492,900	30,000 Added 42.86%	100,000 $1.04 Million
Q1 2019 May 15, 2019	SELL	$17.66 - $30.28 $2.69 Million - $4.61 Million	-152,400 Reduced 68.53%	70,000 $1.74 Million
Q3 2018 Nov 14, 2018	BUY	$29.37 - $49.48 $734,250 - $1.24 Million	25,000 Added 12.66%	222,400 $6.53 Million
Q2 2018 Aug 14, 2018	BUY	$42.06 - $62.4 $412,188 - $611,520	9,800 Added 5.22%	197,400 $8.98 Million
Q1 2018 May 15, 2018	BUY	$50.12 - $67.72 $501,200 - $677,200	10,000 Added 5.63%	187,600 $9.91 Million
Q4 2017 Feb 14, 2018	BUY	$57.69 - $84.58 $1.15 Million - $1.69 Million	20,000 Added 12.69%	177,600 $12.1 Million
Q3 2017 Nov 14, 2017	BUY	$67.17 - $84.81 $10.6 Million - $13.4 Million	157,600	157,600 $13 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.